1、LasmiditanCat. No.: HY-14861CAS No.: 439239-90-4Molecular Formula: CHFNOMolecular Weight: 377.36Target: 5-HT ReceptorPathway: GPCR/G Protein; Neuronal SignalingStorage: Please store the product under the recommended conditions in the COA.Solvent LY573144) is a high-affinity, highly selective 5-HT1F
2、receptor agonist(Ki=2.1 nM), compared with Ki of 1043 nM and 1357 nM at the 5-HT(1B) and 5-HT(1D) receptors, respectively.IC50 value: 2.1 nM (Ki, 5-HT1F); 1000 nM (Ki, 5-HT1B/5-HT1D) 1Target: 5-HT1F receptorin vitro: In vitro binding studies Lasmiditan showed a K(i) value of 2.21 nM at the 5-HT(1F)
3、receptor, compared with K(i) values of 1043 nM and 1357 nM at the 5-HT(1B) and 5-HT(1D) receptors, respectively, a selectivity ratio greater than 470-fold. Lasmiditan showed higher selectivity for the 5-HT(1F) receptor relative to other 5-HT(1) receptor subtypes than the first generation 5-HT(1F) re
4、ceptor agonist LY334370. Unlike the 5-HT(1B/1D) receptor agonist sumatriptan, lasmiditan did not contract rabbit saphenous vein rings, a surrogate assay for human coronary artery constriction, at concentrations up to 100 M 1.in vivo: In two rodent models of migraine, oral administration of lasmidita
5、n potently inhibited markers associated with electrical stimulation of the trigeminal ganglion (dural plasma protein extravasation, and induction of the immediate early gene c-Fos in the trigeminal nucleus caudalis) 1. Two RCTs in the phase II development of lasmiditan was reviewed. In the intraveno
6、us placebo-controlled RCT, lasmiditan doses of 2.5-45 mg were used, and there was a linear association between headache relief (HR) rates and dose levels (P 0.02). For lasmiditan 20 mg, HR was 64 % and for placebo it was 45 % (NS). In the oral placebo-controlled RCT, lasmiditan doses of 50, 100, 200
7、 and 400 mg were used. For HR, all doses of lasmiditan were superior to placebo (P 0.05). For lasmiditan 400 mg, HR was 64 % and it was 25 % for placebo. Adverse events (AEs) emerging from the treatment were reported by 22 % of the patients receiving placebo DescriptionProduct Data Sheet InhibitorsA
8、gonistsScreening Librarieswww.MedChemE1and by 65, 73, 87 and 87 % of patients receiving 50, 100, 200 and 400 mg, respectively 2.REFERENCES1. Nelson DL, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010 Oct;30(10):1159-69.2. Tfelt-Hansen
9、 PC, et al. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J Headache Pain. 2012 Jun;13(4):271-5.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: techMedChemEAddress: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USAwww.MedChemE2
